“The Prolyl Oligopeptidase Inhibitor KYP‑2047 Is Not Readily Bioavailable to Bloodstream Form Trypanosomes and Human Myelocytic Leukemia Cells”. Journal of Pharmaceutical Negative Results, vol. 6, no. 1, Jan. 2015, pp. 7-10, https://mail.pnrjournal.com/index.php/home/article/view/84.